CD19 and acute lymphoblastic leukemia: Preliminary in vitro studies have shown promising results for TriKEs that trigger either NKp46 or NKp30 and CD16a on NK cells, as well as CD19 on ALL cell lines and pediatric B-ALL patients [132].